Title

Presentation

Eli Lilly and Company beats earnings expectations. Reported EPS is $2.58, expectations were $2.47.

Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2024 Earnings Call. At this time all participants are in a listen-only mode. Later we will be conducting a question-and-answer session and instructions will be given at that time. [Operator Instructions] I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations. Please go ahead.

Joe Fletcher: Thank you, Paul, and good morning everyone. Thank you for joining us for Eli Lilly and Company’s Q1 2024 earnings call. I’m Joe Fletcher, Senior Vice President of Investor Relations. And joining me on today’s call are Dave Ricks, Lilly’s Chair and CEO; Anat Ashkenazi, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific Officer and President of Lilly Immunology; Anne White, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly International; Jake Van Naarden, President of Loxo at Lilly; and Patrik Jonsson, President of Lilly Diabetes and Obesity and Lilly USA. We’re also joined by Michaela Irons, Mike Springnether and Lauren Zierki of the IR team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations.

Actual results could differ materially due to several factors, including those listed on Slide 2. Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent filings with the SEC. The information we provide about our products and pipeline is for the benefit of the investment community. It’s not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, please note our commentary will focus on our non-GAAP financial measures. Now I’ll turn the call over to Dave

Dave Ricks: Okay. Thanks, Joe. We’re pleased with our Q1 results and the continued momentum in our business, which positions us well for accelerated growth as this year progresses. Our focus is to bring innovative medicines to people in need. And in 2024, we’re investing in our people, our launches, expanding our pipeline of new medicines, including through business development, and of course accelerating the needed capacity in our manufacturing network. Results this quarter represent a continuation of the strong growth we delivered in 2023. On Slide 4, you can see details of the financial performance and progress related to our strategic deliverables. Revenue grew 26% in Q1 with our new products growing nearly $1.8 billion compared with the same period last year.

We achieved several key pipeline milestones, including the positive Phase 3 results for tirzepatide in moderate-to-severe obstructive sleep apnea, the approval of our multi-dose KwikPen delivery device for Mounjaro in Europe, submission of mirikizumab in the U.S. and in EU for moderately to severely active Crohn’s disease, the resubmission of lebrikizumab in the U.S. for moderate-to-severe atopic dermatitis and the initiation of our Phase 3 study for lepodisiran, evaluating efficacy and reducing cardiovascular risk. Lilly’s top priority is to ensure we execute on our ambitious manufacturing expansion agenda. We recently signed an agreement to acquire an injectable medicine facility from Nexus Pharmaceuticals in Pleasant Prairie, Wisconsin. This state-of-the-art facility has been FDA approved, and we are targeting to initiate production at the end of 2025.

We broke ground earlier this month on our previously announced parenteral manufacturing site in Germany. And in existing facilities, we are working to maximize output and productivity to meet demand. The recent EMA approval and upcoming launch of our multi-dose KwikPen delivery life for Mounjaro will unlock new supply capacity for Europe and other international markets while we are also seeing meaningful progress in the ramp of new lines in existing Lilly and CDMO sites for the United States. We continue to make progress against our plans to increase manufacturing capacity, the most ambitious expansion plan in our company’s history. Lastly, we distributed over $1 billion in dividends during the first quarter. On Slide 5, you’ll see a list of the key events since our Q4 earnings call, including the milestones I mentioned earlier and several other important updates.

So now let me turn the call over to Anat to review our Q1 financial results.

Anat Ashkenazi: Thanks, Dave. Slide 6 summarizes financial performance in the first quarter of 2024. First quarter revenue growth of 26% was driven by new products, primarily Mounjaro and Zepbound. Gross margin as a percent of revenue increased from 78.4% in Q1 2023 to 82.5% in Q1 2024. Gross margin in the quarter benefited from higher realized prices, variable product mix and, to a lesser extent, improved production costs. Marketing, selling and administrative expenses increased 12% primarily driven by promotional efforts supporting current and future launches as well as increased compensation and benefit costs. R&D expenses increased 27%, driven by higher development expenses for late-stage assets, and additional investments in early-stage research, as well as a one-time charge of approximately $75 million associated with the termination of the Verzenio prostate program.

In Q1, we recognized acquired IPR&D charge of $111 million, which negatively impacted EPS by $0.10. Operating income increased 63% in Q1 driven by higher revenue from new products, partially offset by operating expense growth. Our Q1 effective tax rate was 11.9% compared to 12.8% in Q1 2023 driven by a larger net discrete tax benefit reflected in Q1 2024 compared with the same period in 2023. We delivered earnings per share of $2.58 in Q1, a 59% increase compared to Q1 2023, inclusive of the negative impact of $0.10 from acquired IPR&D charges in both periods. On Slide 7, we quantify the effect of price, rate and volume on revenue growth. U.S. revenue increased 28% in Q1 driven by growth of Mounjaro, Zepbound and Verzenio. Unprecedented demand for our incretin medicines led to wholesaler backorders of Trulicity, Mounjaro and Zepbound at quarter end.

Realized prices in the U.S. increased 16%, largely driven by Mounjaro access and savings card dynamics. Moving to Europe. Revenue growth was once again strong, increasing 29% in constant currency, driven primarily by volume from Verzenio and Mounjaro as well as payments associated with the distribution of divestiture agreement. Japan revenue grew 2% in constant currency. Volume growth of 7% was driven by Mounjaro and Verzenio, partially offset by decreased volume for Trulicity and a partnership milestone in the base period. Price declined 5% in the quarter. Moving to China, Q1 revenue increased 4% in constant currency. Volume growth was driven by Tyvyt, partially offset by Olumiant and Cialis. Revenue in the rest of the world increased 31% in constant currency, primarily driven by volume growth from Mounjaro and to a lesser extent, Verzenio and Jardiance.

Slide 8 provides additional perspective across our product categories. First, I would like to highlight Verzenio, which saw worldwide sales increased 40% in Q1, driven by continued volume growth in the early breast cancer indication. Jaypirca revenue increased to $50 million worldwide, representing an acceleration in sequential quarterly growth following the December 2023 approval for the CLO indication. We are looking forward to potentially making this medicine available to even more patients as future Phase 3 trials read out. Next in Q1, Mounjaro sales were $1.8 billion globally, and $1.5 billion in the U.S., up from $568 million and $536 million in Q1 2023, respectively. Sequential quarter-over-quarter revenue for Mounjaro in the U.S. was impacted by a onetime benefit from changes in estimates for rebates and discounts in Q4 2023 as well as lower inventory in the channel in Q4 2024 amidst strong demand.

Access level across commercial end parties were consistent with high levels as we communicated on our last earnings call and near parity with established injectable incretin medicines. The demand for tirzepatide is very strong. And each week, hundreds of thousands of people fill scripts from Mounjaro and Zepbound yet we understand the frustration from those facing prescription delays or uncertainties yet in their medicine. While we are working tirelessly to ramp supply and expect meaningful increases in shipment volumes in the second half of the year, demand continues to outstrip even increased supply. We remain on track to meet expectations we set earlier this year. The production of salable doses of incretin medicine in the second half of 2024 will be at least 1.5 times the salable doses in the second half of 2023.

In the short to midterm, we expect sales growth to primarily be a function of the quantities we can produce and ship. Outside the U.S., we are delighted that the multi-dose KwikPen delivery device from Mounjaro was recently approved in the EU, adding to the UK approval earlier this year. This approval applies to both Type 2 diabetes and product week management indications as they are under the single brand in Europe. While timing for launch will vary by country, we expect to start launching in the EU in coming weeks. In Q1, worldwide Trulicity revenue declined 26%. U.S. Trulicity revenue decreased 30% driven by lower volume, primarily due to supply constraints and competitive dynamics. In addition, sales in international markets were impacted by measures we have taken to minimize disruption to existing patients, including communicated to health care professionals to not start new patients on Trulicity.

Turning to Slide 9, we have seen exceptionally strong U.S. launch progress for Zepbound with over $0.5 billion in sales in Q1. We are rapidly building out access for Zepbound in the U.S. And as of April 1, we have approximately 67% access in the commercial segment. As a reminder, patients within this market is a two-step process typically require individual employers to opt in to an anti-obesity medicine rider following PBM coverage. We are continuing to focus on broadening access, both with PBMs and for employer opt-ins and early progress is encouraging. On Slide 10, we provide an update on capital allocation. Slide 11 shows updated 2024 financial guidance. Given the strength we’re seeing in our business and projections for continued acceleration expected in the second half of the year, we are increasing our full year revenue outlook by $2 billion on the top and bottom ends of the range to be between $42.4 billion to $43.6 billion.

This increase is primarily due to the strong performance of Mounjaro and Zepbound and greater visibility and confidence into our production extension for the remainder of 2024. With this update, year-over-year revenue growth of the company is now expected to be approximately 26% at the midpoint or approximately 35% for the core business, which excludes the impact from global divestitures. Given the update to revenue guidance, we now expect the ratio of gross margin, less OpEx, divided by revenue to be in the range of 32% to 34% on a reported basis and 33% to 35% on a non-GAAP basis, representing further margin expansion. We are reaffirming guidance for other income and expense and tax rate, which now takes into consideration Q1 results. Based on these updates, and inclusive of Q1 IPR&D charges of $0.10 per share, we now expect EPS to be in the range of $13.05 to $13.55 on a reported basis and $13.50 to $14 on a non-GAAP basis.

Now I’ll turn the call over to Dan to highlight progress in R&D.

Dan Skovronsky: Thanks, Anat. Let me start with our exciting announcement from earlier this month. That was a positive Phase 3 results from the SURMOUNT-OSA studies, which evaluated tirzepatide for treatment of adults with obesities and moderate-to-severe obstructive sleep apnea known as OSA. OSA is a sleep-related breathing disorder characterized by complete or partial collapse of the upper airway during sleep. OSA can have serious cardiometabolic complications contributing to hypertension, coronary heart disease, stroke, heart failure, atrial fibrillation and even Type 2 diabetes. The need is significant. OSA impacts 80 million people in the U.S. with more than 20 million people suffering from moderate-to-severe OSA. We also know that a substantial majority, approximately 70% of people with OSA also live with obesity.

While there are pharmaceutical treatments for the excessive daytime sleepiness associated with OSA, tirzepatide could potentially be the first pharmacological treatment for the underlying disease. As shown on Slide 12, SURMOUNT-OSA was comprised of two separate trials run under one master protocol. Study 1 evaluated tirzepatide in participants not currently on positive airway pressure or PAP therapy. While Study 2 evaluates tirzepatide in patients who had used PAP for at least three months prior to the study and plans to continue PAP therapy during the entire course of the trial. A total of 469 participants were enrolled across these studies. Each study randomized participants to either maximum tolerated dose approved for tirzepatide, which can be 10 milligrams or 15 milligrams or to placebo, and patients were followed on therapy for 52 weeks.

On Slide 13, we show the results of Study 1. For the efficacy estimate on mean Apnea-Hypopnea Index, or AHI, tirzepatide led to a mean reduction of 27.4 events per hour compared to a mean AHI reduction of 4.8 events per hour for placebo. This difference was highly statistically significant. AHI baseline values were 52.9% and AHI was reduced by 55% in the tirzepatide arm. We also saw a mean body weight reduction of 18.1%, which for tirzepatide, consistent with our expectations for this study. This was, of course, also statistically significant versus placebo. On Slide 14, we show the results of Study 2. In this population for the efficacy estimand, tirzepatide led to a mean AHI reduction of 30.4 events per hour compared to a mean AHI reduction of 6.0 events per hour for placebo.

The baseline AHI was 46.1% in the tirzepatide arm and mean AHI reduction was 62.8%. Again, we saw impressive weight loss with a mean body weight reduction of 20.1% from baseline. These results were also all highly statistically significant. In both studies, the overall safety profile was similar to previously reported SURMOUNT and SURPASS trials. The most commonly reported adverse events were gastrointestinal related and generally mild-to-moderate in severity, with the most commonly reported gastrointestinal adverse events for patients treated with tirzepatide being diarrhea, nausea, vomiting and constipation. Prior to the study readout, we noted investor questions about what level of weight loss we would see, given several factors that were uniquely combined in the study of tirzepatide.

First, the primary aim of the study was not treatment of obesity. Second, that the population was approximately 70% males, in whom weight loss can be harder to achieve with incretin medicines. Third, there’s a particularly high baseline BMI in this population. And finally, the use of the 10 milligram or 15 milligram maximum tolerated dose approach. We were therefore highly reassured to see weight loss observed across the two studies at 52 weeks was nearly 20% despite this difficult-to-treat population. Consistent with other Phase 3 studies, such as tirzepatide at the 52-week time point, we did not see weight loss plateau. We’ll present detailed results of SURMOUNT-OSA during a symposium at ADA on June 21. Additionally, we plan to submit to the FDA and other global regulatory agencies beginning midyear.

Moving to the other updates across our portfolio. Slide 15 shows select pipeline opportunities as of April 26, and Slide 16 shows potential key events for the year. We’re pleased to share that results were positive in QWINT-4, the first Phase 3 study of insulin efsitora alfa, our once-weekly basal insulin. This study evaluated efsitora compared to insulin glargine in adult participants with Type 2 diabetes who are on multiple daily insulin injections. In the coming weeks, we expect to report top line results from QWINT-4 as well as QWINT-2 which is evaluating efsitora compared to degludec in adults with Type 2 diabetes who are naïve to basal insulin. Together, these are the first two of five studies in the efsitora Phase 3 program. Additional updates in our late-stage diabetes and obesity pipeline include results of the EMPACT-MI study, showing Jardiance had a 10% relative risk reduction in the primary composite endpoint of time-to-first hospitalization due to heart failure or all-cause mortality versus placebo, which did not reach statistical significance.

We’ve completed enrollment for SURMOUNT-MMO with over 15,000 participants, and for both orforglipron studies in chronic weight management, ATTAIN-1 and ATTAIN-2, which together enrolled 4,500 participants. Finally, we’ve now initiated the TRANSCEND Phase 3 program studying retatrutide in Type 2 diabetes. In the cardiovascular disease area, we’re excited to have initiated the Phase 3 trial for lepodisiran, the subcutaneous injectable siRNA. This study will evaluate the efficacy in improving cardiovascular outcomes for participants with high lipoprotein(a), who have cardiovascular disease or at a risk of heart attack or stroke. We are evaluating the efficacy of lepodisiran in both secondary and high-risk primary prevention. And we hope this will one day offer health care providers a treatment option for a broad group of patients and increased cardiovascular risk due to high Lp(a) levels.

Earlier in our diabetes and obesity pipeline, we’ve now initiated a Phase 2 monotherapy study evaluating eloralintide, our selective amylin receptor agonist in obesity. Turning to oncology. We made the decision to terminate for futility, the Phase 3 CYCLONE-3 trial evaluating Verzenio in metastatic hormone-sensitive prostate cancer, following an interim analysis. This concludes development of Verzenio in prostate cancer following last quarter’s announcement that the CYCLONE-2 study did not meet its primary endpoint. In early oncology development, we’ve initiated Phase 1 trials for two new assets. The first is our Nectin-4 ADC, which came from our acquisition of Emergence Therapeutics. The second is PNT2001, which came from our acquisition of Point Biopharma.

We’re encouraged by what we’re seeing in our oncology portfolio and expect 2024 to be particularly productive. Along with the Nectin-4 ADC and PNT2001 start, we expect at least three other new molecules to enter the clinic this year. We look forward to sharing more details with the investment community at an oncology-focused investor event hosted by the Lilly Oncology team. This event will take place on the evening of Sunday, June 2 in Chicago in conjunction with the ASCO Annual Meeting and will also be available via webcast. We plan to provide an update on our oncology strategy and pipeline opportunities. Additional details will be available soon regarding this event. Turning to Neuroscience, last month, we announced that the FDA plans to convene a meeting of the peripheral and CNS Drugs Advisory Committee to discuss donanemab in early symptomatic Alzheimer’s disease.

We expect the Advisory Committee Meeting will take place in mid-2024, but the exact date will be confirmed when it appears in the Federal Register. We expect the focus to be around the safety and efficacy profile of donanemab, along with unique aspects of the clinical program. We remain confident in donanemab’s potential to offer very meaningful benefits to patients and look forward to addressing the FDA’s questions in this form. Additionally, we made the decision to discontinue investigation of GBA1, our gene therapy assets in Gaucher disease type 2. Phase studies in Parkinson’s disease and Gaucher disease type 1 are still underway and have not been impacted by this decision. Finally, in immunology, we’ve submitted mirikizumab to the FDA and EMA for approval for use in adults with moderately to severely active Crohn’s disease.

In the U.S., we’ve resubmitted lebrikizumab’s application to the FDA for moderate to severe atopic dermatitis. This is following a complete response letter based on inspection findings of the third-party manufacturer. As a reminder, the letter stated no concerns with the clinical data package safety or label. We expect regulatory action in the second half of this year. We’re also announcing that in the coming months, we’ll be initiating Phase 3 studies evaluating lebrikizumab in two new indications, chronic rhinosinusitis with nasal polyposis and allergic rhinitis due to perennial allergens. Lebrikizumab will be the first biologic to be evaluated in Phase 3 for allergic rhinitis. We’re optimistic about the potential of lebrikizumab to be an important treatment option in these patient populations as well as in atopic dermatitis.

In earlier-stage immunology development, we’ve advanced our CD19 antibody into Phase 2 for multiple sclerosis. I’ll now turn the call back to Dave for closing remarks.

Dave Ricks: Okay. Thanks, Dan. Before we go to Q&A, let me briefly sum up the progress in our first quarter. Strong revenue growth in Q1 was driven by our recent product launches, primarily Mounjaro and Zepbound. We expect acceleration in revenue growth through the second half of the year as supply of incretin medicines continues to ramp. Significant advances in our pipeline include top line data from tirzepatide and SURMOUNT-OSA, approval of the KwikPen delivery device from Mounjaro in the EU, submission mirikizumab and lebrikizumab as well as initiation of lepodisiran, sorry, Phase 3 study, as Dan just mentioned. We are continuing to invest in recent and upcoming launches, internal and external pipeline development and our manufacturing expansion agenda. This is to sustain our long-term growth outlook. So now, let me turn the call over to Joe to moderate the Q&A session.

Joe Fletcher: Thanks, Dave. We’d like to take questions from as many callers as possible and to conclude our call in a timely manner. So consistent with prior quarters, we’ll respond to one question for callers, so ask that you limit to one question per caller as we’ll end the call at 11:00 a.m. If you have more than one question, you can reenter the queue, and we’ll get your question if time allows. So Paul, please provide instructions for the Q&A session, and we’re ready for our first caller.

Operator: Thank you. At this time, we’ll be conducting a question-and-answer session. [Operator Instructions] And the first question today is coming from Chris Schott from JPMorgan. Chris, your line is live.

Chris Schott: Great. Thanks so much, and congrats on the progress here. I just had a question, just was hoping you could elaborate a bit more on the capacity dynamics that are leading to the guidance raise today. I specifically just looking for little more color, is this more U.S. or international? And should we read this as more capacity in the system than you expected or just a faster ramp of the new plant and may be the same overall capacity as you exit the year? Thanks so much.

Dave Ricks: Thanks, Chris. I’ll hand over to Anat to talk about the guidance raise.

Anat Ashkenazi: Thanks for the question, Chris. And as we’ve mentioned earlier in the year when we issued guidance, we said that the – we expect capacity and supply to ramp towards the second half of the year, and that’s what we’re seeing. Now as a reminder, we do have quite a large number of nodes across our supply chain that have to come online or ramp capacity. We are, if you look at everything work we have under construction, or ramping up, we have six sites right now between the two sites in North Carolina, a site in Ireland [ph], two sites in Indiana, a site in Germany and then the seventh one that we just purchased, they are all either ramping up or under construction. And there are multiple nodes across that supply chain that have to become operational, which requires approval, et cetera, for three products, depending on which product runs on which line, that are planned throughout the year.

Now that we’re four months into the year, we have greater visibility into these nodes of capacity and feel more confident. Just as one example, the approval of the KwikPen in Europe that just came in slightly ahead of our expectation gives us additional confidence in our ability to launch KwikPen for patients in Europe. So it is across our sites globally, as well as ramping up capacity with partners or CDMOs, as well as in existing sites where we’re making investments to expand where we can, or ramp up capacity so it’s across our supply chain. Thanks.

Dave Ricks: Thanks. Next caller, Paul.

Operator: Thank you. The next question is coming from Mohit Bansal from Wells Fargo. Mohit, your line is live.

Mohit Bansal: Great. Thank you very much for taking my question and congrats on the progress. I have a question regarding the pricing. So if you look at the script trend, it seems like there was a little bit of adverse relationship in the pricing versus fourth quarter. Can you comment on that? And how should we think about the cadence of price volume over the quarters for the year? Thank you.

Dave Ricks: Thanks, Mohit. You didn’t say it, but I assume you’re talking about Mounjaro and Zepbound, I’ll hand over to Patrik to make some commentary on net price.

Patrik Jonsson: Thank you very much, Mohit. When you look at the pricing of Mounjaro, I think it’s important to take into account that in the Q4 earnings, we announced onetime adjustment for Mounjaro in Q4, that was quite significant. So that was a onetime adjustment in the base of Q4. When we look forward for the first half of 2024, it’s important to have in mind that we also terminated the $25 saving card 6/30/2023, but patients that were on are grandfather until 6/30/2024. So there would probably be some benefits during the first half of 2024 for Mounjaro. But from the second half of this year, we should expect to see typical pricing headwinds for Mounjaro as well.

Dave Ricks: Thank you. Next question, Paul.

Operator: Thanks. The next question is coming from Umer Raffat from Evercore. Umer, your line is live.

Umer Raffat: Hi guys. Thanks for taking my question. I wanted to focus a quick second on Part D reimbursement dynamics, if I may. And my question is, will tirzepatide be considered differently than a “weight loss drug” to secure Part D reimbursement? And the new indications like sleep apnea, will they considered an applicable drug and not get lumped up as a broad “weight loss drug”? Thank you.

Dave Ricks: Thanks, Umer. I’ll go to Patrik for that question.

Patrik Jonsson: Thank you very much, Umer. I think with the announcement made by the CMS early April to reimburse comorbidities for obesity based on the SELECT trial, we’re also confident that with the new data that we presented just weeks ago in terms of obstructive sleep apnea, that’s going to be reimbursed in Medicare Part D. And we expect similarly for other comorbidities and the readout of HFpEF, assuming that’s positive and approved and later on with the mobility-mortality outcome study. Still, our true north is really to get the true of a treat and reduce obesity at cost, and we strongly believe it’s not a matter of if, but when. We don’t see it likely to pass in 2024, but it’s still a small likelihood that that’s going to happen.

Dave Ricks: Thanks, Patrik. Next question, Paul.

Operator: Thank you. The next question is coming from Seamus Fernandez from Guggenheim. Seamus, your line is live.

Seamus Fernandez: Great. Thanks for the question. So really just wanted to ask, Dan, as you have assessed the Phase 2 SURMOUNT data in NASH just interested to know how you are thinking about those data and the opportunity for tirzepatide in that setting or perhaps if retatrutide remains the right target molecule to move forward there? We’ve had a lot of speculation around some of the comments from the last quarter and just trying to firm that up and also when we’re likely to see those data, I believe, they’re expected at EASL but if that is possible to confirm. Thanks so much.

Dave Ricks: Dan?

Dan Skovronsky: Thanks, Seamus. I’ll start with the last part there. Yes, the abstract was accepted and will be presented at EASL in early June. So that will be the opportunity to see the full NASH package from that Phase 2 trial. Like we said in the last call, really exciting data. We shared some of the top line. I think tirzepatide can have a profound effect on this disease. It’s a Phase 2 trial. Next steps here are to discuss with the FDA what the best path forward could be for tirzepatide. You’re pointing out, though, that we have another choice in retatrutide, which based on biomarker data from earlier studies could also have a profound effect of this disease. That molecule has the addition of glucagon, which is likely to have additional benefits in the liver.

So important opportunities ahead and good to have options as we go into these discussions with regulators. I think for MASH, like other obesity-related or metabolic related diseases, Lilly has a pretty broad portfolio, and we’ll just continue to push the science to make the best possible medicines for patients.

Dave Ricks: Thanks, Dan. Paul, next question.

Operator: The next question will be from Tim Anderson from Wolfe Research. Tim, your line is live.

Tim Anderson: Thank you. You showed a slide, Zepbound has NBRx share market of 57% at end of Q1. That makes it pretty clear that the strongest drug wins. So on that topic, just your latest thinking on upcoming competitor readouts and how they’ll stack up to Zepbound on metrics of weight loss and blood sugar. So specifically, CagriSema from Novo and Amgen’s 133, I know it’s just the best guess, but it’s what we get asked to do. Thank you.

Dave Ricks: Thanks, Tim. Okay. I’ll maybe hand it Dan for some comments.

Dan Skovronsky: Yes, sure, Tim. It’s probably more of your job than ours to speculate on competitor readouts but I’ll take a stab at it since you asked. I think on AMG 133, we’ve just seen really a small amount of data. So probably anything is possible and like you will be interested to see their results. Of course, there’s arguments that can be heard about GIP agonism versus antagonism. We’ve placed our bets, and we like the data we got with GIP agonism. On CagriSema, of course, adding more agonism on different pathways on top of GLP-1 is a good idea. That’s what we have with tirzepatide, as a dual agonist. So CagriSema makes sense. And you’ll note that we’ve advanced our amylin agonist to Phase 2. Tirzepatide already is a dual agonist – tirzepatide already a triple agonist.

There’s probably more we could do here at Lilly. I think across our portfolio, in Phase 1 and Phase 2, we have nine assets that are marked for diabetes or obesity. Many of them could lead to additive weight loss on top of established mechanisms plus two more in Phase 3, of course. So we have a strong portfolio here I think tirzepatide still has unsurpassed efficacy at weight loss, but we’re preparing for our next generation assets as well.

Dave Ricks: Thanks, Dan. Paul, next question.

Operator: The next question will be from Terence Flynn from Morgan Stanley. Terence your line is live.

Terence Flynn: Great. Congrats on all the progress. Just was wondering if you can tell us if the IQVIA prescription data is an accurate representation of tirzepatide volumes or if it’s been underrepresented at all given LillyDirect and what you know about how much is flowing through that channel? And if it is underrepresented, can you help quantify any delta for us. Thank you.

Dave Ricks: Thanks for the question, Terence. I’ll hand to Patrik for commentary on IQVIA and LillyDirect.

Patrik Jonsson: Thanks very much, Terence. When it comes to LillyDirect, I think we are very pleased with the start. And when we look at the utilization by consumers, it’s gaining traction by weeks here. If we look at the TRx data of Q1, particularly for Zepbound, it’s relatively low volume that goes through LillyDirect, slightly higher in terms of NBRx. It’s our understanding that what goes through LillyDirect is not by default captured by IQVIA. But IQVIA has a methodology in place to estimate what goes through LillyDirect as well.

Dave Ricks: Thank you, Patrik. Paul, next question.

Operator: The next question will be from Akash Tewari from Jefferies. Akash your line is live.

Akash Tewari: Thanks so much. So your team presented data on a monotherapy GIP agonist at ADA last year, but it looks like you are moving the amylin into Phase 2. Can you talk about why amylin might be preferred versus GIP as a maintenance regimen for obesity? And how your product could defer versus others when it comes to half-life and preferential agonism versus calcitonin and amylin? Thanks.

Dave Ricks: Thank you, Akash. I’ll hand to Dan for commentary on our amylin.

Dan Skovronsky: Yes, there are a lot of good questions in there. Thanks for following the science so closely. So on the GIP, the long-acting molecule I think primarily in that experiment, we were excited to show the benefits of isolated GIP agonism, just to answer some mechanism of action questions around tirzepatide. But as you point out, there’s potential for that molecule for other indications or as a monotherapy or combination with other mechanisms. But of course, since tirzepatide already includes GIP agonism, we’re also excited to explore other mechanisms. So that’s where the [indiscernible] which is one of nine different mechanisms, as I said a moment ago that we’re exploring the long-acting amylin move forward to Phase 2.

That has potential perhaps as a combination therapy, perhaps as a maintenance therapy, perhaps as a monotherapy, there’s a lot to explore. It’s still very early as it is for all of our mechanisms. So we’ll keep investing, and as we have data to share, we’ll do that.

Dave Ricks: Thanks, Dan. Paul, next question.

Operator: The next question will be from Trung Huynh from UBS. Trung, your line is live.

Trung Huynh: Yes. Hi. Thanks for my question. Just back on CMS recently broadening its coverage for Wegovy for certain heart conditions, I appreciate you mentioned that Teva is the main goal. But do you expect Zepbound to get add to CMS in a similar way as Wegovy? And when could this happen? Could this be after the heart failure data in 3Q? Or do we have to wait for the CVOT data? Thanks very much.

Dave Ricks: Thanks, Trung. I’ll let Patrik respond.

Patrik Jonsson: Thanks, Trung. Now based upon what CMS stated early April, we actually expect to get obstructive sleep apnea for Zepbound covered by CMS and Medicare at the time of launch. And the next one then would be Zepbound assuming a positive readout and approval. And the third one would be the MMO indication that’s the sequence of our plans, assuming everything goes according to plan and we get the approval for both.

Joe Fletcher: Thanks, Patrick. Paul, next question.

Operator: The next question will be from Geoff Meacham from Bank of America. Geoff your line is live.

Geoff Meacham: Good morning guys. Thanks for the question. You guys have been asked on this before, I’m sure, but can you just review the rationale in utilizing the KwikPen just for outside the U.S. markets like you, but I wasn’t sure why this couldn’t apply to the U.S. market and if this also could be a means to relieve capacity looking forward? Thank you.

Joe Fletcher: Thanks, Geoff, for the question. Paul, Dave, you want to weigh in?

Dave Ricks: Yes. Sure. Anyway [ph], I can add to this. As we think we’ve said on several calls now, our goal is to pursue all of the above, basically as it relates to supply options, recognizing the tremendous demand and unmet need and the constraints that exist in scaling the supply chain. So KwikPen uses existing assets, so there was less time lag. We see this first in the UK and now in Europe as a way to meet the needs of those patients. But we haven’t ruled it out in other jurisdictions. And so we’ll continue to look at every option we can to meet the needs of patients with obesity and overweight as well as with diabetes.

Joe Fletcher: Thanks, Dave. Paul, next question.

Operator: The next question is from Kerry Holford from Berenberg. Kerry, your line is live.

Kerry Holford: Hi, I’m going to take a different topic here. Looking Lp(a) your new product, you now said that you’re taking into Phase 3. Can you confirm whether you published the Phase 2 data, haven’t found any. So if I’m correct, when we might see that published? And can you confirm what dose and frequency of administration you’re looking at for that Phase 3 study? And I guess that you appear to be positioned third in that race, would be interested to hear how you expect your drug to be differentiated versus the competitor as already in Phase 3? Thank you.

Dave Ricks: Thanks, Kerry. So a good multipart question, but on Lp(a), happy to talk about lepodisiran. So Dan, do you want to comment on this?

Dan Skovronsky: Yes. Thanks, Kerry, for the good questions here. You’re right, we haven’t yet published a Phase 2 data. But I think we just recently were able to publish the Phase 1 data. That was really exciting and well received. I think one of the things that people noted in our Phase 1 data was a very long durability of action in the very deep reduction in Lp(a) levels following a single dose of lepodisiran. We now have, of course, a Phase 2 data in hand and use that design and to begin the Phase 3 trial. I think we haven’t quite disclosed dose or frequency yet, but I’m sure that will happen in time. You asked about differentiation. I think there’s probably a couple of different potentials for differentiation here versus a shorter-acting ASO into siRNA that are both in Phase 3 studies.

Maybe first is the depth of clearance of Lp(a), we don’t know how much you have to reduce Lp(a) to lead to benefits in cardiovascular outcomes and whether there’s a threshold effect or a floor to this. So the depth of clearance is one. The second, as you asked about, could be frequency of administration or durability of action, those two being closely linked. And the third, of course, is the population that’s being studied to I noted we’re studying secondary as well as primary prevention here. So I think we have a good package with multiple opportunities for differentiation and eager to test the Lp(a) hypothesis here in this Phase 3 study.

Joe Fletcher: Thanks, for the question, Kerry. Paul, next question.

Operator: The next question will be from Steve Scala from TD Cowen. Steve, your line is live.

Steve Scala: Thank you very much. Given that based on all available metrics, the SURPASS-CVOT interim likely already has passed, can you confirm that the only way the trial would have stopped is if there were either a survival benefit or futility and not simply non-inferiority? And anything you can say regarding your confidence in eventually hitting superiority based on what you know so far? Thank you.

Joe Fletcher: Thanks, Steve. Dan, do you want to take the question on SURPASS-CVOT?

Dan Skovronsky: Sure. Thanks, Steve. As you know, we do our best not to comment on interim analysis, although many of our different trials kind of corporate interim analysis. But when we do talk about the risks, unintentional unblinding of results, for that reason, we prefer not to do that. You’re right that the primary analysis of the study and the design is around noninferiority versus what we are ready to know to be a very good drug that reduces cardiovascular risk, and that’s Trulicity. So it’s designed as a noninferiority trial. Of course, when the final data come, we would be delighted to see even superiority. You asked about our confidence. Confidence continues to increase for this readout. In fact, as disclosed in the prepared remarks today, we got additional data here even from the OSA study that should make us feel more confident, not just the benefit of sleep apnea, which itself could lead to cardiovascular benefits, but actually the weight loss.

And I think there are some concerns about weight loss of different populations and different trials and males, females, et cetera. So some of that was discharged here. So remain excited and look forward to getting that data when the study is complete.

Joe Fletcher: Thanks, Dan. Paul, next question?

Operator: The next question will be from Evan Seigerman from BMO Capital Markets. Evan, your line is live.

Evan Seigerman: Hi. Thank you so much for taking my question. I wanted to touch on donanemab with the AdCom approaching. Can you discuss how your – if your confidence has changed in the asset? And maybe any specific points that you will hope will be addressed during this discussion with these outside experts. Thank you so much.

Dave Ricks: Thanks, Evan. Anne, you want to discuss with on the AdCom?

Anne White: Yes. Thanks so much for the question. And we are incredibly confident in donanemab potential and the fact that it offers very meaningful benefits to people with early symptomatic Alzheimer’s disease and just the overall approvability of the package. We do look forward to seeing there’s questions. We haven’t received those yet. I think that what we’ll anticipate really is discussions around the safety and efficacy of donanemab and those – the safety and efficacy profile remain very consistent with what we published and presented. So nothing new there. We do expect there’s a couple of unique aspects to our trial that we anticipate they’ll want to discuss. One is around limited duration dosing. We think this is an incredibly important feature of donanemab, the chance to stop dosing when you’ve cleared the plaques and donanemab clears them robustly and rapidly.

So, we think that allows for this limited duration dosing approach. So we really do look forward to getting into that data and having the advisors see that and respond to it. Another unique aspect is assessing tau at baseline. This is important for the field that we understand the prognostic factor of tau, and that was able to be earned. But what we saw in the trial was all patients benefited regardless of tau level with those early in the disease doing even better. It’s one of the reasons that we remain so enthusiastic about TRAILBLAZER 3. And while Dan didn’t mention that in his remarks, I think he remain even more enthusiastic about the opportunity to intervene earlier based on what we saw in that early population, the people with low tau and those that had no tau with such strong biomarker results.

I think you probably remember the data that patients in the earliest part of our study had a 60% slowing. And we believe that could be even stronger as you get into the earlier patients that are preclinical. But maybe just one remark. In the meantime, though, this is not time loss. We’ll continue to make sure the health care system is ready. We’re going to make sure that we launch into an even stronger market with potential approval. So we’re making the most of this time and look forward to the AdCom, [ph] as Dan said, in mid-2024, answering any questions that they have.

Joe Fletcher: Thank you, Anne. Paul, next question?

Operator: The next question will be from David Risinger from Leerink Partners. David, your line is live.

David Risinger: Thanks very much. And let me add my congrats on the progress and the guidance raise. So my question is on orforglipron. Novo Nordisk has raised some concerns about the scalability of orforglipron manufacturing given its complexity, I haven’t spoken to Novo directly, but someone told me that they mentioned there are 35 steps in the process. I don’t know if that’s true. But could you please discuss how Lilly is building out its manufacturing capacity and whether the company expects to be able to meet global demand in the Western world after launch in 2026? Or whether we, the investment community, should expect supply constraints and should be guarded about how we try to model orforglipron’s ramp after launch? Thank you.

Joe Fletcher: Thanks, Dave. I’ll hand over to Dave Ricks here.

Dave Ricks: Okay. Great. Dave, great to hear from you. I mean, first of all, it is true that our orforglipron is a complicated large, small molecule, a large small molecule, if you were, and there are many steps in the process. You can read about them in our patent filings, I think. But Lilly, maybe unlike other companies, we made small molecules for a long time. We’re capable of doing it. We understand how to put them together, and we’ve got a defined process to do it for orforglipron. So the API production were a long process and maybe complicated relative to other small molecules is something we’re super confident in and have our arms around. The finish process is really the big advance over using injectables because here, we’re just tablet stamping or tablet – capsule making, which are dry processes, we understand extremely well.

I think the big gain here will be the fact that both for synthetic chemistry and capsule making and tablet making, there is already capacity on planet Earth that is significant. And so unlike the parenteral side where we’ve been talking about injectables and new capacity needs to be built, in which we’re doing aggressively as a not [ph] commented on earlier, here, there’s a lot of partners we can access as well as our own substantial network or dry product go finish [ph] and API production. So pretty confident here. Now when we stick the landing on exact doses and quantities in every instance? We’re not guaranteeing that, but I think the picture will be quite a bit different should orforglipron prove to be safe and effective in the Phase 3 studies.

Again, that’s in 2025, so we can expect launch maybe a year after that, and that’s an important event in the time course of the incretin class.

Joe Fletcher: Thanks Dave. And thanks Dave Risinger for the question. Next question, Paul?

Operator: Next question is coming from Louise Chen from Cantor. Louise, your line is live.

Louise Chen: Hi. Thanks for taking my question. I just wanted to ask you about your next wave of obesity drug. It looks like you’re about half a dozen of these in development. And where do you see the most differentiate yourself?

Dave Ricks: Thanks. Dan, do you want to comment on the earlier phase obesity?

Dan Skovronsky: Yes. Thanks, Louise. We’re excited about the portfolio of earlier-stage obesity molecules. I think there’s a number of opportunities for improvement over – even an excellent drug like tirzepatide. We think about the quality of weight loss as one aspect. So for example, even on tirzepatide, we see the ratio of lean to fat mass approved as patients lose weight on these drugs could we make it improve even faster with the muscle stimulating agents like bimagrumab, but maybe that’s under investigation. Tirzepatide is very well tolerated, but some people stop taking it because of GI side effects. Could we have drugs that have fewer side effects? But maybe that could be possible. Tirzepatide is given as a once a weekly injection, most patients find that to be acceptable, but probably with less frequent injections that could lower the burden on manufacturing and make it easier to use for patients, so that’s another avenue of exploration.

There are some patients who don’t achieve their desired levels of weight loss even on a powerful drug like tirzepatide, and so that’s another avenue. Finally, across different indications, and I spoke earlier of NASH, that are related to metabolic disease. There could be different activities that proved more or less beneficial for these other related diseases. So that’s another avenue of differentiation. I think we’re just at the beginning of probably what will be seen as a multi-decade investments in treating abnormal metabolism and all diseases that come with that. And I’m really proud and pleased that really has what must be the strongest pipeline in this area in the industry.

Dave Ricks: Thank you, Dan. Paul, next question.

Operator: The next question is from Chris Shibutani from Goldman Sachs. Chris, your line is live.

Dave Ricks: Thanks, Chris. Paul, the next question?

Chris Shibutani: Can you hear me?

Dave Ricks: Yes, there you are. Go ahead, Chris.

Chris Shibutani: Great. Thank you. Wanted to ask about supply and dynamic and the demand and when those two might come closer together? Previously, not you been quite specific in your vocabulary and saying that that was something that could possibly happen in 2025. Dave, you were in front of a group that we hosted and I think you gave a little bit of a broader range. What’s the latest that you would like to communicate based upon all the progress that you’re making, the acquisition of Wisconsin facility, et cetera, about a potential timing for that supply-demand dynamic to come closer together?

Dave Ricks: Thanks, Chris. Anat?

Anat Ashkenazi: Yes. Let me start on this. So I would say that, as I said in my prepared remarks, we expect that the supply and demand situation will remain quite tight in the near-term as well as the mid-term. And just to clarify, it’s not that we have a production issue or manufacturing facilities are progressing incredibly well, and I’m incredibly proud of the work done by our M&Q colleagues around the world. Clearly, we have sites working 24/7. We’re doing construction overnight. We’re making the right investments and progressing rapidly as you’ve seen evidence by the results as well as the raise we did for the year. But the demand is strong, but shouldn’t be a surprise given the health benefits that these products provide to patients, highly efficacious and safe medicines.

And I expect that this will continue through the year, even with the significant ramp that we have and we’ll add more supply across different presentations, both with the auto-injector as well as the Kwikpen. But even with that, I expect that the demand will be – will outpace supply through this year, potentially next year, obviously, we’ll see. We’ll continue to invest and ramp as we go into next year, but it could be quite some time. We talked earlier about orforglipron, should we have positive Phase 3 readout that provides another relief valve in terms of just offering a different presentation, as Dave mentioned, which utilizes a different set of infrastructure within our manufacturing organization available capacity globally. So it will be in a stepwise fashion.

We’ll continue to update investors as we progress through the year and coming years.

Dave Ricks: Thanks, Anat. Paul, next question.

Operator: Next question will be from Carter Gould from Barclays. Carter, your line is live.

Carter Gould: Great. Thanks. Good morning. Congrats on all progress. I wanted to dive into bimagrumab ahead of the Phase 2b data forthcoming. Can you talk for a bit around the importance of showing statsig or clear dose response across the composition of the weight loss drivers and maybe as well as the importance of not blunting the overall weight loss as you contemplate a move to Phase 3 potentially? Thank you.

Dave Ricks: Thanks, Carter, for the question. Dan, you want to comment on the bimagrumab?

Dan Skovronsky: Yes. Thanks, Carter. It’s a good question. Bimagrumab is a very different mechanism of weight loss versus incretins, but one that we think could be important in combination with incretins. So bimagrumab, we think will likely have important effects on adipose tissue as well as muscle mass. And so our hope is to see increased muscle mass and increased ratio, I should say of lean to fat mass by combining bimagrumab with incretins. In this present study, it’s being evaluated both as monotherapy in combination with semaglutide at different doses. So we’ll see if weight loss effects on fat tissue stack, and we’ll see if effects on lean body mass that we’re seeing in previous bimagrumab monotherapy studies work in combination with incretin. Looking forward to seeing that, too.

Joe Fletcher: Thanks Dan. Paul, next question?

Operator: The next question is coming from Kripa Devarakonda from Truist Securities. Kripa your line is live.

Kripa Devarakonda: Hey guys. Thank you much for taking my question and congrats on all the progress. I have a question about your radio pharma pipeline. You mentioned PNT2002 in your oncology pipeline. Can you talk about how you see that advancing? And given what you’ve seen so far, where you see this being placed in the landscape in terms of market share? Thank you.

Dave Ricks: Thanks, Kripa, for the question. Jake, calling you to maybe opine a little bit on our radioligand efforts, PNT2001 in particular?

Jake Van Naarden: Yes, happy to. Thanks for the question. We’re really excited about bringing radiopharmaceuticals into the portfolio by way of the acquisition of Point Biopharma, and we are supplementing that acquisition with additional work through our Discovery Labs and the ability to make these medicines ourselves. So I expect we’ll have more to talk about in terms of additional medicines over the course of the next couple of years in addition to PNT2001. But specific to that question, 2001 is a PSMA-directed therapy for prostate cancer conjugated to actinium, the altimeter. And I think while the actinium holds a lot of promise over lutetium, particularly in the context of creating double-stranded DNA breaks versus single stranded and the ability to perhaps drive more efficacy for patients for prostate cancer.

I think one of the limitations of the existing agents is that they probably cause too much salivary gland toxicity to be real durable products. And so the POINT team designed a novel PSMA-directed ligand with increased tumor uptake relative to the salivary gland in order to drive more therapeutic index using actinium as the payload. So we’re just getting started with the Phase 1 experience right now. So I don’t have a lot to say about what we’re seeing just yet. But the preclinical package looked really interesting and differentiated from the other PSMA ligands that exist out there. So we’re looking forward to putting it through its Phase 1 paces, and we’ll see what we have. Depending on the clinical profile, I think there’s the potential to improve outcomes in patients that have already seen a lutetium based agent, maybe go ahead of that and compete with the lutetium based agents or perhaps even go even earlier in therapy as PSMA expression really exists in the continuum of prostate cancer care.

So more to come on that as we define the clinical profile in the Phase 1.

Dave Ricks: Thanks, Jake. Paul, I think we’ve got time for maybe one more question. We’re right at 11:00. So maybe a final question in the queue.

Operator: Okay. And the final question today is coming from James Shin from Deutsche Bank. James, your line is live.

James Shin: Hey, good morning guys. Thanks for question. I just wanted to try and reconcile the guidance lift with the 1.5 times sellable doses being maintained. Thank you.

Dave Ricks: Okay. James, maybe I’ll give Anat to talk about the guidance and how the guidance raised relates to the 1.5 – those comments.

Anat Ashkenazi: Yes. So let’s start with the 1.5 dose – sellable dose comment that I made on the guidance call in February. So that reference is not a number of devices, but number of sellable doses. And as we ramp up capacity for KwikPen, recall that unlike the single-use vial or the auto-injector, that KwikPen is a multidose device that has multiple dose available for patients. That common [ph] referred to the second half of this year versus the second half of last year. So we’re expecting that total sellable doses this year in the second half will be at least 1.5 times where we were second half of last year. That remains unchanged. But the level of confidence we have in our ability to progress on each node of our capacity that’s coming online or will get approved, et cetera, has just increased.

There are multiple of these throughout the year. Multiple of these have occurred. Some will occur, as I gave the KwikPen as one example. You think about a construction of a site, for example, Concord in North Carolina, which we said will become operational by end of the year, and we’ll start seeing products next year. That construction has concluded. Lines are installed, and we need to run qualifications, get approval, et cetera. There are multiple nodes of these across our own manufacturing sites as well as external and that they all need to come online to get to where we need in terms of the full year guidance. But our confidence as the year progresses, a year has progressed, our confidence in that has increased, but it remains the – at least 1.5 times.

Dave Ricks: Thanks, Anat. Great. Well, thanks for your time today, everyone, and we appreciate you participating in today’s earnings call and your interest in our company. Please follow up with the IR team if you have any additional questions that we didn’t address today, and have a great day. Thanks.

Operator: Thank you. And ladies and gentlemen, this does conclude our conference for today. This conference will be made available for replay beginning at 1:00 p.m. today running through June 4 at midnight. You may access the replay system at any time by dialing 800-332-6854 and entering the access code 317750. International dialers can call at 973-528-0005. Again, those numbers are 800-332-6854 and 973-528-0005 with the access code 317750. Thank you for your participation. You may now disconnect your lines.